Secretory leukocyte protease inhibitor as a marker of proinflammatory response in children with community-acquired pneumonia

  • V. M. Dudnyk National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • V. Yu. Pasik National Pirogov Memorial Medical University, Vinnytsya, Ukraine
Keywords: secretory inhibitor of leukocyte proteinase, cytokines, C-reactive protein, alanine aminotransferase, aspartate aminotransferase, liver, community-acquired pneumonia in children.

Abstract

The study of the secretory leukocyte protease inhibitor (SLPI) level in children with pneumonia is important because it may indicate protease-antiprotease imbalance and predict local regulation of proteolytic activity at different degrees of pneumonia in children. The aim of the study was to assess the level of SLPI as a marker of proinflammatory response in the serum of young children, depending on the severity of pneumonia, including the presence or absence of lesions of the hepatobiliary system. The study investigated the SLPI as a marker of the inflammatory response in children with community-acquired pneumonia, depending on the severity of the disease, lesions of the hepatobiliary system, age and sex. The level of SLPI in the serum was determined by enzyme-linked immunosorbent assay using a diagnostic test system from “IMMUNOTECH” (France). “IBM SPSS Statistica” Version 12 (20) was used for statistical processing of the results. It was found that the course of community-acquired pneumonia is accompanied by an increase in the serum level of SLPI in children in parallel with the severity of the disease. The development of a lesion from the GBS reduces the level of a protease inhibitor in the blood serum of children with pneumonia, which indicates a decrease in the body's defense systems. In children 1-12 months, the level of SLPI is higher than in children 13-36 months, which indicates more significant protective capabilities of the body of children in the first year of life. It has been shown that an increase in the level of SLPI correlates with an increase in the level of inflammatory cytokines, which indicates a unidirectional change in the formation of local immunity in response to damage to the lung tissue. At the same time, a negative correlation was found between the level of SLPI and the activities of AST, GGT and CRP (rxy= -0.054; rxy= -0.215; rxy= -0.215, respectively), which indicates a violation of liver function during the development of an infectious-inflammatory process in the body. Studies of the nature of the effects of cytokines and protease inhibitors (protective factors) on the development and maintenance of inflammatory process in the lungs in young children with community-acquired pneumonia with lesions of the hepatobiliary system may be the basis for predicting its course.

References

[1] Bradshaw, J. L., Caballero, A. R., Bierdeman, M. A., Adams, K. V., Pipkins, H. R., Tang, A., ... & McDaniel, L. S. (2018). Pseudomonas aeruginosa protease IV exacerbates pneumococcal pneumonia and systemic disease. Msphere, 3(3), e00212-18. doi: 10.1128/mSphere.00212-18
[2] Camper, N., Glasgow, A. M. A., Osbourn, M., Quinn, D. J., Small, D. M., McLean, D. T., ... & Taggart, C. C. (2016). A secretory leukocyte protease inhibitor variant with improved activity against lung infection. Mucosal immunology, 9(3), 669-676. doi: 10.1038/mi.2015.90
[3] Chiang, T. Y., Tsao, S. M., Yeh, C. B., & Yang, S. F. (2014). Matrix metalloproteinases in pneumonia. Clinica Chimica Acta, 433, 272-277. doi: 10.1016/j.cca.2014.03.031
[4] Dvorak, J., & Horn, M. (2018). Serine proteases in schistosomes and other trematodes. International journal for parasitology, 48(5), 333-344. doi: 10.1016/j.ijpara.2018.01.001
[5] Habgood, A. N., Tatler, A. L., Porte, J., Wahl, S. M., Laurent, G. J., John, A. E., ... & Jenkins, G. (2016). Secretory leukocyte protease inhibitor gene deletion alters bleomycin-induced lung injury, but not development of pulmonary fibrosis. Laboratory investigation, 96(6), 623-631. doi: 10.1038/labinvest.2016.40
[6] Jin, Y., Li, Y., Wang, X., & Yang, Y. (2019). Secretory leukocyte protease inhibitor suppresses HPV E6-expressing HNSCC progression by mediating NF-κB and Akt pathways. Cancer cell international, 19(1), 1-19. doi: 10.1186/s12935-019-0942-7
[7] Leung, A. K., Wong, A. H., & Hon, K. L. (2018). Community-acquired pneumonia in children. Recent patents on inflammation & allergy drug discovery, 12(2), 136-144. doi: 10.2174/1872213X12666180621163821
[8] Liu, L., Ma, Z., Sun, W. W., & Cao, J. P. (2018). Upregulated expression of secretory leukocyte protease inhibitor in lung by inhalation of high concentration of sulfur dioxide. Chinese medical journal, 131(16), 2005-2007. doi: 10.4103/0366-6999.238143
[9] Nugteren, S., & Samsom, J. N. (2021). Secretory Leukocyte Protease Inhibitor (SLPI) in mucosal tissues: Protects against inflammation, but promotes cancer. Cytokine & Growth Factor Reviews, (59), 22-35. doi: 10.1016/j.cytogfr.2021.01.005
[10] Nugteren, S., Goos, J. A., Delis-van Diemen, P. M., Simons-Oosterhuis, Y., Lindenbergh-Kortleve, D. J., van Haaften, D. H., ... & Samsom, J. N. (2020). Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis. Oncoimmunology, 9(1), 1832761. doi: 10.1080/2162402X.2020.1832761
[11] Reitman, S., & Frankel, S. (1957). A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. American journal of clinical pathology, 28(1), 56-63. doi: 10.1093/ajcp/28.1.56
[12] Samejima, T., Nagamatsu, T., Akiba, N., Fujii, T., Sayama, S., Kawana, K., ... & Fujii, T. (2021). Secretory leukocyte protease inhibitor and progranulin as possible regulators of cervical remodeling in pregnancy. Journal of Reproductive Immunology, 143, 103241. doi: 10.1016/j.jri.2020.103241
[13] Satici, C., Demirkol, M. A., Altunok, E. S., Gursoy, B., Alkan, M., Kamat, S., ... & Esatoglu, S. N. (2020). Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19. International Journal of Infectious Diseases, 98, 84-89. doi: 10.1016/j.ijid.2020.06.038
[14] Tang, R., Botchway, B. O., Meng, Y., Zhang, Y., Zhou, C., Jiang, J., & Liu, X. (2020). The inhibition of inflammatory signaling pathway by secretory leukocyte protease inhibitor can improve spinal cord injury. Cellular and molecular neurobiology, 40(7), 1067-1073. doi: 10.1007/s10571-020-00799-1
[15] Van Den Boogaard, F. E., Brands, X., Duitman, J., De Stoppelaar, S. F., Borensztajn, K. S., Roelofs, J. J., ... & van der Poll, T. (2018). Protease-activated receptor 2 facilitates bacterial dissemination in pneumococcal pneumonia. The Journal of infectious diseases, 217(9), 1462-1471. doi: 10.1093/infdis/jiy010
[16] Yun, K. W., Wallihan, R., Juergensen, A., Mejias, A., & Ramilo, O. (2019). Community-acquired pneumonia in children: myths and facts. American journal of perinatology, 36(S 02), S54-S57. doi: 10.1055/s-0039-1691801
[17] Zhong, Q. Q., Wang, X., Li, Y. F., Peng, L. J., & Jiang, Z. S. (2017). Secretory leukocyte protease inhibitor promising protective roles in obesity-associated atherosclerosis. Experimental Biology and Medicine, 242(3), 250-257. doi: 10.1177/1535370216672747
Published
2021-06-26
How to Cite
Dudnyk, V. M., & Pasik, V. Y. (2021). Secretory leukocyte protease inhibitor as a marker of proinflammatory response in children with community-acquired pneumonia. Biomedical and Biosocial Anthropology, (43), 29-33. https://doi.org/10.31393/bba43-2021-05